Group 1: Company Overview and Strategic Partnerships - The company has established a strategic partnership with Defo Capital, aiming to become a major platform for integrating past investment businesses in the health sector, with a goal of "building China's DSM" [2][3] - The collaboration with DSM-Firmenich has been ongoing since 2024, focusing on achieving annual procurement targets and strengthening revenue foundations through mutual trust and business empowerment [4][5] Group 2: Product Development and Innovations - The company has developed a synthetic biology business strategy since 2022, focusing on enhancing production efficiency and reducing costs, with key products including the steviol glycoside RM series and biopolysaccharides [3][4] - The steviol glycoside RM2 product received FDA GRAS certification last year, with domestic certification pending final review, highlighting its advantages in sweetness, taste, solubility, and cost control [3] - Biopolysaccharides have been industrialized and are currently applied in the daily chemical sector, with ongoing efforts to obtain relevant certifications [3] Group 3: Manufacturing and Operational Enhancements - The company has upgraded its Indiana plant to a comprehensive plant extraction facility, focusing on brand raw materials and ensuring local resource utilization to enhance market competitiveness [5][6] - Future capital expenditures are expected to be minimal as the company shifts focus to operational efficiency and market expansion, particularly in the stevia extraction and synthetic biology sectors [6] Group 4: Market Trends and Regulatory Environment - Over 100 countries have implemented sugar tax policies, indicating a global trend towards health consciousness and diabetes management, which may positively impact the company's natural sweetener business [7] - The company is monitoring developments in the CBD market, with recent positive signals from U.S. policies regarding CBD inclusion in healthcare plans, while emphasizing the need for clear regulatory standards [7]

Group 1: Transaction Overview - The transaction with Defo Capital involves the transfer of 8.09% equity from the original controlling shareholder and the acquisition of 95.5% equity in Beijing Jinkangpu, aimed at vertical integration in the industry [3][4] - The acquisition is expected to enhance the company's capabilities in customer service, channel diversification, and resource integration, providing strong support for future development [2][3] Group 2: Strategic Alignment - Defo Capital's focus on the health sector aligns with the company's strategic direction, recognizing the potential in natural health components [4][5] - The company has over 20 years of industry experience, a robust production capacity, and a comprehensive quality control system, making it an attractive partner for Defo Capital [5][6] Group 3: Business Development Plans - The company plans to focus on two main directions for its synthetic biology business: developing proprietary products and providing industrialization services for external clients [6][7] - The RM2 product, a key natural sweetener, is expected to reshape the market, with plans for promotion through high-quality product and formulation services [7][8] Group 4: Capacity and Utilization - The company has established multiple extraction facilities, ensuring sufficient capacity, but current utilization rates are low due to new facilities not yet being operational [8][9] - Future capacity release will depend on sales growth of core products and the introduction of new synthetic biology products into the market [9][10] Group 5: Global Operations - The upgrade of the U.S. extraction facility aims to enhance supply chain security and meet global customer demands, focusing on producing raw materials advantageous in North America [9][10] - The company plans to optimize overseas capacity and improve product delivery efficiency to achieve significant operational improvements in the U.S. market [9]